Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment.
Chun-Jen LiuI-Shyan SheenChi-Yi ChenWan-Long ChuangHorng-Yuan WangKuo-Chih TsengTing-Tsung ChangJenny YangBenedetta MassettoVithika SuriGregory CamusDeyuan JiangFangqiu ZhangAnuj GaggarTsung-Hui HuYu-Chun HsuGin-Ho LoChi-Jen ChuJyh-Jou ChenCheng-Yuan PengRong-Nan ChienPei-Jer ChenPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Among HCV/HBV coinfected patients treated with direct-acting antivirals for HCV, HBV virologic reactivation occurred in a majority of patients during treatment and follow-up. In most patients, HBV virologic reactivation was asymptomatic; only a small proportion initiated HBV treatment. Notably, clinical reactivation may still occur >3 months after end of therapy.